Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 15/20 | 0.46 |
| ▸ | ITGAV | P06756 | 15/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807565 | 0.91 | ITGB3 (0.51) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL6810762 | 0.88 | ITGB3 (0.47) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL6811418 | 0.88 | ITGB3 (0.51) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL7744368 | 0.87 | ITGB3 (0.51) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL8365736 | 0.87 | ITGB3 (0.51) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL23999261 | 0.80 | KEAP1 (0.52) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL22738697 | 0.80 | KEAP1 (0.51) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL6811498 | 0.79 | ITGB3 (0.40) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL6807615 | 0.79 | ITGB3 (0.58) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL16994856 | 0.77 | ITGB3 (0.52) | ITGB3ITGAVITGA5ITGB1ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818659-B2 | TARGETS AND BINDS BIOLOGICAL RECEPTORS; MEDICAL DIAGNOSIS; MAGNETIC RESONANCE, X-RAY, ULTRASOUND, AND CONTRAST IMAGING | BRISTOL-MYERS SQUIBB PHARMA, INC. | 2004-11-16 | — | — | US | disclosed |
| US-20040087603-A1 | (2S) -2-AMINO-4-(2-AMINO-(3,4,5,6-TETRAHYDROPYRIMIDIN-4-YL) BUTANOYL AND ITS USE IN CYCLIC AND ACYCLIC PEPTIDES | LANTHEUS MEDICAL IMAGING, INC. | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087603-A1 | (2S) -2-AMINO-4-(2-AMINO-(3,4,5,6-TETRAHYDROPYRIMIDIN-4-YL) BUTANOYL AND ITS USE IN CYCLIC AND ACYCLIC PEPTIDES | VIP, ARGLU1, NGLY1 | ITGB3 1291/4885ITGAV 1016/4885ITGA5 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.